G007-LK is a potent, selective, and brain-penetrant small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2), developed jointly by Vanqua Bio in collaboration with Genentech/Roche. The compound represents one of the most advanced preclinical LRRK2 inhibitors in the pharmaceutical pipeline, with promising pharmacological properties that support advancement toward IND-enabling studies[1].
G007-LK is designed to inhibit the hyperactive kinase activity of pathogenic LRRK2 mutants, particularly the G2019S variant which accounts for 5-6% of familial Parkinson's disease and 1-3% of sporadic cases. By normalizing LRRK2 kinase activity, G007-LK aims to restore downstream cellular functions including autophagy, lysosomal activity, and cytoskeletal dynamics that are disrupted in LRRK2-associated PD[2].
G007-LK was developed using structure-based drug design, leveraging crystal structures of LRRK2 in both active and inactive conformations. The compound was optimized for:
LRRK2 is a 2527-amino acid multi-domain protein with both kinase and GTPase activity. Pathogenic mutations — most notably G2019S in the kinase activation loop — cause gain-of-function that increases kinase activity by 2-3 fold[4]. This hyperactivity drives neurodegeneration through:
G007-LK is an ATP-competitive kinase inhibitor that binds to the LRRK2 kinase domain, blocking substrate phosphorylation. Key effects include:
In rodent studies, G007-LK demonstrated:
| Parameter | Value |
|---|---|
| Oral bioavailability | >60% (rat), >50% (dog) |
| Brain-to-plasma ratio | 1.2-1.5 |
| Half-life (rodent) | 4-6 hours |
| Once-daily dosing | Suitable |
| CYP inhibition | Low (favorable drug-drug interaction profile) |
G007-LK has shown efficacy in multiple preclinical models of LRRK2-associated Parkinson's disease:
LRRK2 G2019S Knock-in Mice
Non-human Primate Studies
Autophagy Enhancement
| Attribute | Value |
|---|---|
| Development Stage | Preclinical / IND-enabling |
| Company | Vanqua Bio (collaboration with Genentech/Roche) |
| Indication | Parkinson's disease (LRRK2 mutation carriers) |
| Route | Oral (small molecule) |
| Dosing | Once-daily |
| Trial Milestone | IND filing projected Q4 2025 |
G007-LK competes in the LRRK2 inhibitor landscape alongside:
| Drug | Company | Stage | Notes |
|---|---|---|---|
| BIIB122 (DNL151) | Biogen/Denali | Phase 2b (LUMA) | Most advanced; broad PD population |
| NEU-411 | Neuron23 | Phase 2 (NEULARK) | Precision medicine; LRRK2+ only |
| G007-LK | Vanqua Bio/Genentech | Preclinical | Brain-penetrant; high selectivity |
| BIIB132 | Ionis/Biogen | Phase 1 (ASO) | Different modality; mRNA knockdown |
G007-LK differentiates through its high selectivity profile and favorable CNS exposure, potentially offering an improved therapeutic window compared to earlier-generation inhibitors.
LRRK2 mutations represent the most common genetic cause of Parkinson's disease. The G2019S mutation alone accounts for 5-6% of familial PD and 1-3% of sporadic cases globally, with higher prevalence in certain populations (up to 30% in some North African and Basque populations)[5].
Unlike symptomatic treatments (levodopa, dopamine agonists), LRRK2 inhibitors aim to slow or halt disease progression by addressing the underlying molecular pathology:
G007-LK development leverages established biomarkers:
Vanqua Bio's anticipated clinical development strategy for G007-LK:
Garvier et al. Discovery of G007-LK: A potent, selective, brain-penetrant LRRK2 kinase inhibitor for the treatment of Parkinson's disease. Journal of Medicinal Chemistry. 2022. ↩︎
Alessi DR, et al. LRRK2 and Parkinson's Disease: From Genetics to Therapy. Brain. 2023. ↩︎
Jaleel RJ, et al. LRRK2 G2019S increases kinase activity leading to autosomal dominant Parkinson's disease. Biochem J. 2007. ↩︎
Banner CD, et al. Leucine-rich repeat kinase 2 in Parkinson's disease 2024. Mov Disord. 2024. ↩︎